Opus Genetics Announces Positive Phase 3 Trial Results

Opus Genetics ( (IRD) ) just unveiled an announcement.

On June 26, 2025, Opus Genetics announced positive topline results from its VEGA-3 Phase 3 trial for Phentolamine Ophthalmic Solution 0.75%, aimed at treating presbyopia. The trial met its primary and key secondary endpoints, showing significant improvement in near visual acuity without compromising distance vision. With a strong safety profile and no serious adverse events reported, these results bolster Opus Genetics’ plan to submit an FDA application in the second half of 2025. This development could position the company favorably in the ophthalmic treatment market, potentially benefiting millions affected by presbyopia.

The most recent analyst rating on (IRD) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.

Spark’s Take on IRD Stock

According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.

Opus Genetics faces significant financial challenges, with declining revenues and persistent losses undermining its financial stability. The technical indicators suggest a bearish trend, while the negative corporate event further highlights financing difficulties. These factors contribute to a low overall score, indicating a high-risk investment with uncertain prospects.

To see Spark’s full report on IRD stock, click here.

More about Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company based in Research Triangle Park, NC, focused on developing gene and small molecule therapies for vision-threatening eye diseases. The company’s pipeline includes AAV-based gene therapies targeting inherited retinal diseases and small molecule therapies for other ophthalmic disorders, such as presbyopia.

Average Trading Volume: 893,999

Technical Sentiment Signal: Sell

Current Market Cap: $57.88M

See more insights into IRD stock on TipRanks’ Stock Analysis page.